Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
NINGBO INNO PHARMCHEM CO.,LTD. looks ahead at the evolving landscape of anticoagulation therapy, considering advancements and future directions beyond the established efficacy of factor Xa inhibitors like rivaroxaban. While rivaroxaban has significantly improved patient care, the pursuit of even safer and more effective antithrombotic strategies continues.
Direct Thrombin Inhibitors: Alongside factor Xa inhibitors, direct thrombin inhibitors, such as dabigatran, represent another class of oral anticoagulants that directly target thrombin, the final enzyme in the coagulation cascade. These agents offer similar benefits in terms of oral administration and predictable action.
Novel Anticoagulant Targets: Research is ongoing to identify and develop inhibitors of other critical factors in the coagulation pathway. Targeting factors like FXI (Factor XI) is a promising area. Inhibiting FXI may offer antithrombotic benefits with a potentially lower risk of bleeding compared to current anticoagulants. This is an active area for 'drug discovery in anticoagulation'.
Personalized Anticoagulation: The concept of personalized medicine is also gaining traction. This involves tailoring anticoagulant therapy based on an individual's genetic makeup, comorbidities, and specific risk factors. Pharmacogenomics and advanced diagnostic tools are expected to play a larger role in optimizing treatment choices and dosages.
New Delivery Systems and Antidotes: Innovations in drug delivery systems could further enhance the convenience and efficacy of anticoagulants. Additionally, the development of specific antidotes for newer anticoagulants remains an important area of research to manage bleeding complications effectively.
Research into Non-Pharmacological Interventions: Alongside pharmacological advancements, research continues into mechanical methods for VTE prevention, such as intermittent pneumatic compression devices, and the role of lifestyle modifications and exercise in managing thrombotic risk.
The continuous innovation in anticoagulation therapy, exemplified by the success of factor Xa inhibitors like rivaroxaban, promises a future with more targeted, safer, and personalized approaches to managing bleeding and clotting disorders, directly impacting the 'prevention and treatment of thrombotic disorders'.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
